First-in-class
immunotherapy
to fight tumors
from within

Learn why HERVs are an ideal target and about Hervolution's technology video
Know more

Shifting the paradigm in cancer immunotherapy

by targeting the human endogenous retroviruses
 to treat cancer

Know more
Watch the video

Human Endogenous Retroviruses (HERVs) are well recognized as tumor specific antigens, but they have been undruggable until now.

Hervolution is developing immunotherapies designed to overcome the limitations of cancer vaccines by targeting HERV tumor antigens with a powerful technology that stimulates both arms of the immune system, the humoral and the cellular response.

Our technology

Meet the team

At Hervolution, we challenge biotechnology as we know it by shifting the paradigm in cancer immunotherapy. We have established a great team of scientists, advisors and entrepreneurs with long-standing experience to drive our research every day.

Meet our team
Jordi Naval
Jordi Naval, MSc
Chief Executive Officer
Peter-Holst
Peter Holst, MD, PhD
Chief Scientific Officer
Hamina-Patel
Hamina Patel, MD, PhD
Chief Medical Officer

Latest news

View all news
Robert Langer
pexels-photo-3786247
pexels-photo-259251
flight-sky-earth-space
pexels-photo-3938022
Inprother_Jordi_Naval_CEO
_DSC2407final
Hervolution_Sharon_Glynn
inprotherblogpost
inprotherblog
Robert Langer
pexels-photo-3786247
pexels-photo-259251
flight-sky-earth-space

Hervolution ApS
Novo Nordisk BioInnovation Institute COBIS
CVR: 33968426
Ole Maaløes Vej 3, 2200 Copenhagen N, Denmark
Copyright 2023 ©

Privacy Policy | Legal Advice

Hervolution ApS
Novo Nordisk
BioInnovation Institute COBIS
CVR: 33968426
Ole Maaløes Vej 3,
2200 Copenhagen N,
Denmark
Copyright 2023 ©

Privacy Policy | Legal Advice